Jiang Y Z, Barrett J
Bone Marrow Transplantation Unit, Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD 20892-1652, USA.
Leuk Lymphoma. 1997 Dec;28(1-2):33-42. doi: 10.3109/10428199709058328.
CD4+ T-cells have emerged as important cells in the initiation and delivery of the GVL response. Nevertheless it seems likely that they act in concert with other T-cells and NK cell effectors to produce the full in vivo effect of GVL. How they interact with other effectors is yet to be determined. Furthermore it is very likely that different hematological malignancies have different susceptibility to attack by various lymphocyte subsets, depending upon their MHC expression, nature of the antigens presented and other properties not yet defined. Here we specifically focus on the role of CD4+ T-cells in mediating GVL, particularly in chronic myeloid leukemia. Candidate antigens recognised by CD4+ cells are described and new approaches to GVL modulation in clinical bone marrow transplantation are discussed.
CD4 + T细胞已成为移植物抗白血病（GVL）反应启动和发挥作用过程中的重要细胞。然而，它们似乎与其他T细胞和自然杀伤（NK）细胞效应器协同作用，以产生GVL在体内的完整效应。它们如何与其他效应器相互作用仍有待确定。此外，很可能不同的血液系统恶性肿瘤对各种淋巴细胞亚群攻击的敏感性不同，这取决于它们的主要组织相容性复合体（MHC）表达、呈递抗原的性质以及其他尚未明确的特性。在这里，我们特别关注CD4 + T细胞在介导GVL中的作用，尤其是在慢性髓性白血病中的作用。描述了CD4 + 细胞识别的候选抗原，并讨论了临床骨髓移植中GVL调节的新方法。
